Eric R. Braverman, M.D.

Founder and President of PATH Foundation NY, a non-profit research organization devoted to establishing how the brain functions and using that information to develop practical diagnostic and treatment methods that improve wellbeing and increase longevity. Dr. Braverman has established PATH Foundation NY with Kenneth Blum, PhD, centering on the brain-the most important organ in medicine from pediatrics to geriatrics-and has continued the fight to shift United States health care spending to a neuropsychiatric focus: brain first. Dr. Braverman has published with NYS Governor Cuomo’s former Commissioner of Health, Nirav Shah, on the obesity epidemic, and has lead the emergency preparedness movement of securing potassium iodide in the event of a nuclear disaster alongside distinguished West Point graduate General Bernard Loeffke, PhD, amongst other notable government officials and radiation specialists. He is the author of several best-selling books on brain/body health and nutrition. He is also the Founder and Medical Director of PATH Medical, where his life’s work is dedicated to serving patients by balancing the brain’s chemistry and conquering obesity, addiction, and memory loss. He utilizes the integration of all medical specialties for the singular purpose of life extension through total health.

Kenneth Blum, Ph.D.

Scientific Director of PATH Foundation NY, Adjunct Professor in the Department of Psychiatry at the McKnight Brain Institute of the University of Florida College of Medicine and Department of Psychiatry at the Keck Medical School USC. Dr. Blum has one of the longest careers in neuroscience with the discovery of neuropsychiatric genetics, which targets the brain’s genetic code linked to neuropsychiatric addictions as well as other medical diseases/disorders. Dr. Blum coined “Brain Reward Cascade and Reward Deficiency Syndrome (RDS)” and is credited as the lead author in the first association of the Dopamine D2 receptor gene with severe alcoholism (JAMA, 1990). He is credited with co-discovering the first gene (Dopamine D2 Receptor Gene) to associate with not only alcoholism, but also reward dependence. He is also the father of Neuroadaptagen Amino-Acid Therapy (NAAT) for the recovery field.

Jean Lud Cadet, M.D.

Senior Investigator of the Molecular Neuropsychiatry Research Branch at the National Institute of Drug Abuse (NIDA). Dr. Cadet continues to add to the literature investigating brain function as a collective epigenetic instrument that affects the DNA over generations, in which human brain chemistry greatly interacts with their DNA infrastructure.

Yi Zhang, Ph.D.

Fred S. Rosen endowed professor of pediatrics and professor of genetics at Harvard Medical School, and Director of Stem Cell Institute at Harvard. Dr. Zhang has pioneered the epigenetic chromatin and histone regulation of DNA genetics and addictive behavior highlighting the effects of cocaine, but also the implications of other related addictions, in which individuals cross addict: alternating from food to marijuana to cocaine to sex to gambling and continuing this cycle.

Vincent Pieribone, Ph.D.

John B. Pierce Laboratory Fellow, Professor of Cellular and Molecular Physiology and Neuroscience at the Yale School of Medicine, Research Associate at the American Museum of Natural History, and on the Scientific Board of Directors at the Mystic Aquarium and Center for Exploration. Dr. Pieribone is the pioneer on utilizing fluorescent light as a tool for brain imaging, shedding light on all aspects of neurological function.

Eric Nestler, MD, Ph.D.

Dean for Academic Affairs, Director of the Friedman Brain Institute, Nash Family Professor of Neuroscience, Chairman of the Department of Neuroscience, Professor of Pharmacology and Systems Therapeutics, and Professor of Psychiatry at Mount Sinai. Dr. Nestler has confirmed the dopamine hypothesis of cocaine reward and he has established an epigenetic basis of mental illness and its crossover to addiction. He has further identified that addictive reward cascade begins with deficits of neurotransmitters in the brain.

David Self, Ph.D.

Dr. Self is the Wesley Gilliland Professor of Biomedical Research in the Department of Psychiatry at the University of Texas Southwestern Medical Center. Dr. Self, who initially trained in Dr. Nestler's laboratory, has pioneered work on the role of neuroadaptations in addictive behavior, and has identified important neurobiological mechanisms underlying drug craving and relapse to drug seeking.

Gene-Jack Wang, MD

Senior Clinician and Clinical Director in the Laboratory of Neuroimaging at the National Institute on Alcohol Abuse and Alcoholism (NIAAA). Dr. Wang, who has worked alongside Nora Volkow, MD, is the pioneer on utilizing PET scans to identify the dopaminergic deficiencies that both create the reward cascade of drug addiction and break it down.

Elyssa Margolis, Ph.D

Assistant Professor and Director at the Wheeler Center for the Neurobiology of Addiction in the Department of Neurology at the University of San Francisco School of Medicine. Dr. Margolis has pioneered the role of the brain and VTA and dopaminergic neurons in food addiction and reward deficiency syndrome (RDS).

Rajendra Badgaiyan, MD

Dr. Badgaiyan is the Director and Principal Investigator of Molecular and Functional Brain Imaging Laboratory and Director of the University Laboratory for Advanced Radiochemistry. Dr. Badgaiyan graduated from Gandhi Medical College, Bhopal in India and completed his psychiatry residency training at Harvard Medical School. He had postdoctoral training in cognitive neuroscience at University of Oregon, University of Pittsburgh and Harvard University. He also had training in molecular imaging at Massachusetts General Hospital, Boston, and clinical research training at MIT. He is board certified in General Psychiatry and in Addiction Medicine.

Hermann Steller, Ph.D.

Strang Professor and Head of the Laboratory of Apoptosis and Cancer Biology at Rockefeller University, and Investigator at the Howard Hughes Medical Institute. Dr. Stellar has identified new techniques to block forms of apoptosis or cell death. Virtually, all drug-addicted individuals have accelerated cell death of neurons, causing further dopamine and neurotransmitter deficiencies.

Joseph Maroon, MD, FACS

Professor and Vice Chairman and Heindl Scholar in Neuroscience in the Department of Neurosurgery at the University of Pittsburgh. Dr. Maroon has identified a cascade of injury from head trauma and its impact on growth hormone, DHEA, cortisol, psychiatric states, cognitive abilities and its antecedents to destructive behavior.

Peter K. Thanos, Ph.D.

Senior Research Scientist at the Behavioral Neuropharmacology and Addiction Research Center at the University at Buffalo, NY. Dr. Thanos has raised the possibility that human repair is attainable by finding more value in work and love, than the empty thrills of addiction where the brain has better modulation control of neuropsychiatric disorders.

Richard Smayda, DO

Graduate of the University of New England College of Osteopathic Medicine, Resident at Northside Hospital and Tampa Bay Heart Institute, and Integrative Family Practitioner at PATH Medical. Dr. Smayda has spent his entire career healing the brain with nutrients, targeting food addiction, and working with 12-step addiction groups in primary care, where 25% of patients are abusing drugs. He focuses on the brain chemistry and its natural/nutritional methods of repair, including the utilization of Campral.



Conference Options

Remote Participation

Award Dinner Options